Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Free Cash Flow (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Free Cash Flow for 11 consecutive years, with -$17.6 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 136.27% to -$17.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$74.0 million through Dec 2025, down 201.61% year-over-year, with the annual reading at -$74.0 million for FY2025, 201.61% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$17.6 million at Cartesian Therapeutics, down from -$15.0 million in the prior quarter.
  • The five-year high for Free Cash Flow was $16.2 million in Q3 2024, with the low at -$31.7 million in Q4 2021.
  • Average Free Cash Flow over 5 years is -$12.2 million, with a median of -$12.1 million recorded in 2021.
  • The sharpest move saw Free Cash Flow plummeted 352.76% in 2023, then surged 273.79% in 2024.
  • Over 5 years, Free Cash Flow stood at -$31.7 million in 2021, then surged by 62.0% to -$12.1 million in 2022, then tumbled by 92.97% to -$23.3 million in 2023, then skyrocketed by 67.96% to -$7.5 million in 2024, then plummeted by 136.27% to -$17.6 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$17.6 million, -$15.0 million, and -$17.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.